Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users
← catalyst calendarNCT06659029 · readout in 1,700 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With PPD Development, LP.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
442estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-01 | actual | When the study began enrolling |
| Primary completion | 2031-04-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-04-15 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Systemic Lupus Erythematosus
Intervention
- Drug: Anifrolumab — also filed as Saphnelo
Primary outcome
what the primary-completion date above is the date OFComposite outcome of all major congenital malformations (MCMs)
measured From date of conception (DOC) to pregnancy outcome for fetal losses or 12 months of infant age for live births
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed